) is a practical measure of average glucose levels during the preceding 2 to 3 months. [1] [2] [3] [4] In 2009, after review of available evidence, an International Expert Committee recommended the use of HbA 1c to diagnose diabetes. 5 Extensive work has been done by the NGSP (formerly, the National Glycohemoglobin Standardization Program) to standardize methods for measuring HbA 1c and to identify methods that provide accurate HbA 1c measurement even in the presence of hemoglobin variants. 6 Sickle cell trait (SCT) is the most common hemoglobin variant in the United States, with 8% to 10% of black people affected by SCT compared with less than 1% of white people. 7, 8 Red blood cells of individuals with normal hemoglobin contain approximately 97% HbA, whereas red blood cells of individuals with SCT contain approximately 60% to 70% HbA and 30% to 40% HbS. 9 Although data are limited, it is hypothesized that the presence of HbS results in a shorter lifespan for red blood cells. [9] [10] [11] [12] This would result in less available time for hemoglobin glycation, which in turn may influence the interpretation of HbA 1c in relationship to the glucose values they intend to represent. Correct interpretation of HbA 1c values in individuals with SCT is important because it directly affects efforts that use HbA 1c for screening, diagnosis, and monitoring of diabetes and prediabetes. Accordingly, the objectives of this study were to (1) examine the association between HbA 1c and SCT while controlling for other measures of glucose (fasting and 2-hour glucose) levels, (2) compare the prevalence of prediabetes and diabetes by SCT status, and (3) determine if SCT modifies the discriminative ability of HbA 1c to identify individuals with prediabetes or diabetes.
Methods

Study Population
This retrospective study pooled data from participants who self-identified as African American from 2 established community-based cohorts, the Coronary Artery Risk Development in Young Adults (CARDIA) study and the Jackson Heart Study (JHS), to examine the association of SCT with HbA 1c , controlling for fasting glucose or 2-hour glucose levels. Details regarding the design of each study have been published. 13, 14 In brief, the CARDIA study enrolled, 
Covariate Assessment
Details regarding data collection procedures for CARDIA Serum ferritin was measured at year 20 in CARDIA and at baseline in JHS. Previous diabetes diagnosis was defined as self-report of a physician's diagnosis. Current use of diabetes medications was defined as use of diabetes medications in the 2 weeks prior to the examination.
SCT Status
In CARDIA, SCT status was determined with available DNA samples from the 10-year follow-up and afterwards using single-gene, single-nucleotide polymorphism (SNP) genotyping with TaqMan SNP Genotyping Assays (Life Technologies). In JHS, genotype data for rs334 encoding the sickle hemoglobin mutation (HBB p.Glu7Val) was obtained through whole-exome sequencing using data from baseline. Sickle cell trait was defined as the presence of 1 abnormal allele for HbS. els were measured in CARDIA and obtained during a standard oral glucose tolerance test, using 75 g of glucose solution. The coefficient of variation for glucose measures ranged from 1.6% to 3.8% (eTable 1 in the Supplement).
HbA 1c Measures
Two NGSP-certified assays were used to measure HbA 1c , both using high-performance liquid chromatography. In JHS, a Tosoh 2.2 was used at baseline and a Tosoh G7 (variant mode) was used at the 5-and 10-year follow-ups. In CARDIA, a Tosoh G7 (variant mode) was used at the 20-and 25-year follow-up. According to the NGSP, neither Tosoh 2.2 nor Tosoh G7 (variant mode) has experienced clinically significant interference in those with SCT. 6 The coefficient of variation for HbA 1c assays rangedfrom1.2%to1.9%(eTable1intheSupplement).
Main Outcome Measure
The main outcome measure, HbA 1c, was assessed at multiple time points and pooled cross-sectionally to examine the association between HbA 1c , modeled as a continuous variable, and SCT, adjusting for fasting or 2-hour glucose measures. Prespecified secondary outcomes include prediabetes, diabetes, and combined prediabetes or diabetes, which were defined using the following measures based on cutpoints established by the American Diabetes Association 21 :
(1) fasting glucose levels (prediabetes, 100-<126 mg/dL; diabetes, ≥126 mg/dL; and combined prediabetes or diabetes, ≥100 mg/dL), 2-hour glucose levels (prediabetes, 140-<200 mg/dL; diabetes, ≥200 mg/dL; and combined prediabetes or diabetes, ≥140 mg/dL), and HbA 1c levels (prediabetes, 5.7%-<6.5%; diabetes, ≥6.5%; combined prediabetes or diabetes, ≥5.7%). (To convert glucose from mg/dL to mmol/L, multiply by 0.0555.)
Statistical Methods
Baseline characteristics of participants with and without SCT were compared using χ 2 tests and analysis of variance for discrete and continuous variables, respectively. All visits with concurrent measurement of HbA 1c and fasting glucose or HbA 1c and 2-hour glucose levels were included in the analyses. Mean HbA 1c values were calculated by SCT status across a range of glucose categories in 10-mg/dL increments for fasting glucose (<80-≥150 mg/dL) and in 20-mg/dL increments for 2-hour glucose levels (<80-≥200 mg/dL). Generalized estimating equations (GEE) using random effects at the participant level and an exchangeable correlation matrix to account for correlation among repeated measures were used to assess the association of SCT with HbA 1c controlling for fasting glucose levels. 22 A multistep approach was used to examine the robustness of findings to model specification. First, unadjusted GEE models were fit using HbA 1c as the outcome, SCT as the exposure, and glucose as the primary covariate. Next, GEE analyses were adjusted for the following potential confounders that were identified a priori based on the literature: age, sex, BMI, ferritin levels, eGFR, physician-diagnosed diabetes, use of diabetes medications, and study cohort. [23] [24] [25] In addition, multiplicative
SCT × glucose interaction was tested in unadjusted and adjusted models. Analyses were repeated using 2-hour glucose measures in lieu of fasting glucose measures as the main covariate. Model fit was compared using quasi-likelihood under the independence-model criterion. 26 Prespecified subgroup analyses were conducted among participants not taking diabetes medications and in groups of participants stratified by cohort. Interaction by cohort and HbA 1c assay on the association between SCT and HbA 1c was tested. Next, among a subset of participants with no previous diabetes or current use of diabetes medications, GEE analyses with a Poisson distribution and an identity link function were used to estimate the unadjusted prevalence of prediabetes and diabetes by SCT status.
27
In the same subset of participants, GEE analyses with a Poisson distribution and a log link function (sometimes called a modified Poisson model) were used to generate predictive probabilities that were then used in logistic regression models to compare the discriminative ability of HbA 1c levels to identify the combined presence of prediabetes or diabetes. 28 A combined outcome of prediabetes or diabetes was used due to consideration of sample size. Area under the receiver operating characteristic (AUROC) curves were calculated for HbA 1c levels in those with and without SCT. Unpaired comparisons of the AUROC curves were conducted to assess the discriminatory power of HbA 1c by SCT status.
29,30
Complete case analysis was performed for adjusted analyses because data were more than 98% complete, with the exception of ferritin (7% missing). A 2-sided P value of ≤.05 was used for level of significance. Analyses were performed using SAS statistical software version 9.4 (SAS Institute Inc).
Results
Baseline Characteristics
A total of 7938 participants were enrolled at baseline, of whom 2637 were in CARDIA and 5301 in JHS. a Baseline for this study was the first visit at which a participant had HbA 1c and fasting or 2-hour glucose measured concurrently. For CARDIA participants, this was either the year-20 or year-25 follow-up examination. For JHS participants, this was either examination 1, 2, or 3.
b Hemoglobin was only measured in 2976 participants, all of whom are from JHS (ie, 64% of the total analytic sample).
c Ferritin was only measured in 4278 participants (ie, 93% of the total analytic sample).
d Two-hour glucose was only measured in 1222 participants all of whom are from CARDIA and are not taking diabetes medications (ie, 26% of the total analytic sample).
e Diagnosed diabetes is defined as self-reported use of diabetes medications or self-reported physician diagnosis.
f Diabetes medications is defined as use of a medication for the treatment of diabetes taken in the 2 weeks prior to the study examination. Figure 1A ; P = .01 in adjusted analyses, Figure 1B ). Results were similar in analyses stratified by study cohort and when excluding 1302 observations from participants taking diabetes medications at the time of examination (eTable 3 in the Supplement). There was no evidence of interaction by HbA 1c assay (P = .43 for SCT × fasting glucose × HbA 1c assay) or by study cohort (P = .63 for SCT × fasting glucose × study cohort). Results for 2-hour glucose measures revealed similar HbA 1c differences by SCT status. For a given 2-hour glucose level, HbA 1c values were statistically significantly lower in those with SCT (mean HbA 1c , 5.35%) vs in those without SCT (mean HbA 1c , 5.65%), for a mean HbA 1c difference of −0.30% (95% CI, −0.39% to −0.21%; P < .001). Hemoglobin A 1c levels remained significantly lower in those with SCT in adjusted analyses (mean difference in HbA 1c , −0.38%; 95% CI, −0.49% to −0.28%; P < .001). The difference in HbA 1c levels by SCT status was greater at higher 2-hour glucose concentrations (P = .03 for interaction in unadjusted analyses, Figure 1C ; P = .03 in adjusted analyses, Figure 1D ).
Prevalence of Prediabetes and Diabetes
Among a subset of participants with no prior diagnosis of diabetes or current use of diabetes medications (7449 observations for fasting glucose and HbA 1c ; 1869 observations for 2-hour glucose and HbA 1c ), the prevalence of prediabetes and diabetes was not significantly different among participants with vs without SCT when defined using fasting glucose (28.6% with vs 25.0% without SCT for prediabetes; P = .12; 2.5% with vs 3.6% without SCT for diabetes; P = .25) or 2-hour glucose values (15.9% with vs 12.9% without SCT for prediabetes, P = .45; and 3.6% with vs 3.3% without SCT for diabetes; P > .89; Figure 2 ). In contrast, the prevalence of prediabetes and diabetes was statistically significantly lower among participants with SCT when defined using HbA 1c values (29.2% with vs 48.6% without SCT for prediabetes and 3.8% with vs 7.3% without SCT for diabetes; P < .001 for all comparisons, Figure 2 ).
Discriminative Ability of HbA 1c to Identify Prediabetes or Diabetes
In the same subset of participants without diabetes or diabetes medication use, the discriminative ability of HbA 1c to identify the presence of prediabetes or diabetes was statistically significantly lower among participants with SCT (AUROC, 0.70; 95% CI, 0.65-0.74) vs without SCT (AUROC, 0.77; 95% CI, 0.75-0.78; absolute difference, 0.07; 95% CI, 0.02-0.12) when using fasting glucose-defined prediabetes or diabetes (P < .01, Figure 3A) . The same held true among participants with SCT (AUROC, 0.60; 10 95% CI, 0.47-0.72) vs those without SCT (AUROC, 0.74; 95% CI, 0.71-0.78; absolute difference, 0.15; 95% CI, 0.02-0.28) when using 2-hour glucose-defined prediabetes or diabetes measures (P = .02, Figure 3B ). We consider 2 ways in which SCT could modify the ability of HbA 1c to accurately reflect past glycemia. First, the lifespan of the red blood cells in persons with SCT may be shortened compared with those with normal hemoglobin, resulting in less time available for glycation. However, the evidence to support this hypothesis remains limited and conflicting. [9] [10] [11] [12] Second, the presence of HbS can result in assay interference with common HbA 1c measurement techniques. Current testing on HbA 1c laboratory methods uses a relative bias of plus or minus 7.0% to classify clinically significant interference from hemoglobin variants. 6 Although the assays used in this study report no clinically significant interference in individuals with SCT, the possibility of minor interference that could potentially explain our findings cannot be ruled out. Irrespective of the mechanism, our results suggest that currently accepted clinical measures of HbA 1c do not reflect recent past glycemia in the same way in African Americans with and without SCT, as evidenced by significantly lower HbA 1c values at the same glucose concentration in those with vs without SCT. These results could have clinically significant implications. As a screening tool, an HbA 1c value that systematically underestimates long-term glucose levels may result in a missed opportunity for intervention. In the present study, using standard clinical HbA 1c criteria to identify prediabetes and diabetes resulted in identifying 40% fewer cases of prediabetes and 48% fewer cases of diabetes among participants with SCT compared with those without SCT, while glucose-based methods resulted in a similar prevalence regardless of SCT status (Figure 2) . The discriminative ability of HbA 1c concentration to identify individuals with prediabetes or diabetes was significantly lower in those with vs those without SCT (Figure 3 ). These findings raise the possibility of benefit from incorporating information on hemoglobin variants into clinical guidelines for interpreting HbA 1c values for screening and diagnosis of prediabetes and diabetes. Because black people typically have a higher prevalence of diabetes and experience a number of diabetic complications at higher rates than white people, the cost of inaccurately assessing risk and treatment response is high. [34] [35] [36] In our study, African Americans with and without SCT had relatively high HbA 1c levels with mean values greater than 5%. This is possibly due to the higher values often found in black people than in white people. 37, 38 Future studies that include biracial populations should further investigate HbA 1c differences by race in relation to hemoglobinopathies. We also noted that individuals with SCT had a lower eGFR as was observed previously by Naik and colleagues. 39 Future studies should focus on whether a possible delay in the diagnosis and treatment of prediabetes and diabetes in those with SCT could explain their lower kidney function. Strengths of our study include the availability of detailed information on demographics, medical history, and clinical measures as well as the reproducibility of findings across 2 different versions of the Tosoh HbA 1c assay (2.2 and G7) and across 2 different measures of glucose concentration (fasting and 2-hour glucose).
This study has a number of limitations. Despite pooling data from 2 large cohorts, a relatively small number of participants had SCT (367 participants). Although, to our knowledge, this is the largest study to date examining the association between HbA 1c , SCT, and other glucose measures, further studies including biracial populations and other hemoglobin variants are needed to confirm and complement our findings. Second, validation of these findings with other HbA 1c assays would help explain the potential mechanisms of the disparate HbA 1c -glycemia association between those with and without SCT. Third, even though multiple measures of glucose were available and findings were consistent with fasting and 2-hour glucose measures, these measures cannot fully represent average glycemia over the prior 2 to 3 months, which might lower the precision of our estimates. However, our findings were robust in analyses adjusted for potential confounding variables and in various sensitivity analyses suggesting that the likelihood of such bias is low. Fourth, a large number of participants were excluded from analyses due to missing data on SCT status, HbA 1c measures, or glucose measures; however, participants excluded were comparable with those in the analytic sample with the exception of a lower BMI at baseline among those excluded. In addition, no clinical outcomes were assessed in this study. Whether the findings in this study have clinical implications is unclear.
Conclusions
Among African Americans from 2 large, well-established cohorts, participants with SCT had lower levels of HbA 1c at any given concentration of fasting or 2-hour glucose compared with participants without SCT. These findings suggest that HbA 1c may systematically underestimate past glycemia in black patients with SCT and may require further evaluation.
